面板测序揭示罕见可能致病基因变异与幼年起病系统性红斑狼疮不同临床表型及结局相关
该研究基于2018年设计的测序面板对348例幼年起病系统性红斑狼疮(jSLE)患者行靶向富集与二代测序,约3.5%检出致病基因变异;『遗传性』SLE患儿起病年龄更小、黑非洲/加勒比裔更多,器官受累与损伤更少,但神经精神受累随时间出现,一线治疗强度较低而二、三线药物使用更多,且诊断时抗dsDNA抗体阳性率更高、末次随访ANA、抗La和抗Sm抗体阳性率降低。
要点
- 约3.5%的jSLE患者检出致病基因变异,与更早起病年龄及黑非洲/加勒比裔背景相关。
- 『遗传性』SLE器官受累与损伤较少,但神经精神受累随时间出现,一线治疗强度较低而二、三线药物使用更多。
- 『遗传性』SLE诊断时抗dsDNA抗体阳性率更高,末次随访ANA、抗La和抗Sm抗体阳性率降低。
核心结论
- 约3.5%的jSLE患者携带致病基因变异,与更早起病年龄和不同临床特征相关。
- 作者认为在『遗传性』SLE中,自身抗体阳性可能是组织损伤的结果,可解释免疫复合物介导的肾脏和血液系统受累较少。
- 作者认为常规测序可实现患者分层、风险评估和靶向治疗,从而提高疗效并减少毒性。
研究设计与样本
- 基于2018年设计的测序面板,对348例患者行靶向富集和二代测序以识别致病基因变异。
- 研究将测序结果与人口学、临床和治疗相关数据集整合分析。
- 研究比较了『遗传性』SLE亚组与其余SLE患者的人口学、临床和实验室特征。
主要发现
- 约3.5%的jSLE患者检出致病基因变异。
- 与其余队列相比,『遗传性』SLE累及更年幼儿童和更多黑非洲/加勒比裔患者。
- 『遗传性』SLE患者器官受累和损伤较少,神经精神受累随时间出现。
- 『遗传性』SLE患者一线治疗选择较不积极,但二线和三线药物使用更多。
- 『遗传性』SLE与诊断时抗dsDNA抗体阳性相关,且末次随访时ANA、抗La和抗Sm抗体阳性率降低。
关键数值与推荐
- 致病基因变异在jSLE患者中检出率约为3.5%。
- 『遗传性』SLE与诊断时抗dsDNA抗体阳性及末次随访ANA、抗La、抗Sm抗体阳性率降低相关。
临床怎么用
- 作者认为常规测序可能有助于患者分层、风险评估和靶向治疗,从而提高疗效并减少毒性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Juvenile-onset systemic lupus erythematosus (jSLE) affects 15-20% of lupus patients. Clinical heterogeneity between racial groups, age groups and individual patients suggests variable pathophysiology. This study aimed to identify highly penetrant damaging mutations in genes associated with SLE/SLE-like disease in a large national cohort (UK JSLE Cohort Study) and compare demographic, clinical and laboratory features in patient sub-cohorts with 'genetic' SLE vs remaining SLE patients. METHODS: Based on a sequencing panel designed in 2018, target enrichment and next-generation sequencing were performed in 348 patients to identify damaging gene variants. Findings were integrated with demographic, clinical and treatment related datasets. RESULTS: Damaging gene variants were identified in ∼3.5% of jSLE patients. When compared with the remaining cohort, 'genetic' SLE affected younger children and more Black African/Caribbean patients. 'Genetic' SLE patients exhibited less organ involvement and damage, and neuropsychiatric involvement developed over time. Less aggressive first line treatment was chosen in 'genetic' SLE patients, but more second and third line agents were used. 'Genetic' SLE associated with anti-dsDNA antibody positivity at diagnosis and reduced ANA, anti-LA and anti-Sm antibody positivity at last visit. CONCLUSION: Approximately 3.5% of jSLE patients present damaging gene variants associated with younger age at onset, and distinct clinical features. As less commonly observed after treatment induction, in 'genetic' SLE, autoantibody positivity may be the result of tissue damage and explain reduced immune complex-mediated renal and haematological involvement. Routine sequencing could allow for patient stratification, risk assessment and target-directed treatment, thereby increasing efficacy and reducing toxicity.
引用
- Charras A, Haldenby S, Smith EMD, et al. Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE. Rheumatology (Oxford). 2023. PMID: 35532072. doi:10.1093/rheumatology/keac275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。